1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
OPTUS Pharmaceutical Co. Ltd.

OPTUS Pharmaceutical Co. Ltd.

KKRX:131030
5,940.00
KRW
-10.00
(-0.17%)
801.71EPS
16.83P/E
234.35BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3,418.92
2,086.93
2,362.65
2,738.63
3,051.37
3,041.16
3,702.05
3,770.8
3,575.21
3,698.29
4,765.45
5,363.16
5,609.79
5,785.95
Basic EPS, GAAP
181.49
610
631
704
789
613
894
893
617
316
708
675
731
801.71
Free Cash Flow per Basic Share
541.99
530.64
257.96
636.16
1,049.97
879.82
797.76
719.32
-221.86
-249.37
599.36
-1,102.37
-1,854.63
-2,330.57
Dividend per Share
- -
- -
98.56
99.97
100.01
100.04
99.99
101.2
100.06
101.14
99.79
99.92
- -
- -
Book Value per Share
3,005.32
3,512.04
4,011.45
4,609.9
5,301.97
5,813.32
6,600.21
7,411.07
7,918.38
8,207.04
8,811.11
9,403.11
9,498.25
10,133.74
Tangible Book Value per Share
2,987.25
3,491.93
4,011.45
4,609.9
5,301.97
5,813.32
6,600.21
7,411.07
7,918.38
8,207.04
8,811.11
8,352.11
8,607.95
9,255.97
Basic Weighted Avg Shares
8
16
16
16
16
16
16
16
16
16
15
15
16
16
Sales/Revenue/Turnover
26,850
32,566
38,559
44,720
49,808
49,625
60,441
60,827
57,316
58,658
72,426
81,905
87,161
91,625
Operating Margin (%)
25.3
28.06
26.76
25.45
25.33
21.59
25.13
25.49
18.27
8.96
11.3
10.49
10.18
11.85
Depreciation Expense
1,678
1,687
2,340
2,797
2,937
3,158
2,620
2,585
2,423
3,463
4,238
3,977
4,708
4,890
Net Income, GAAP
1,425
9,519
10,298
11,496
12,879
10,003
14,596
14,405
9,892
5,012
10,760
10,308
11,358
12,696
Effective Tax Rate (%)
- -
- -
4.54
1.56
1.5
11.32
11.11
22.14
5.61
26.6
17.04
14.69
- -
0.87
Profit Margin (%)
5.31
29.23
26.71
25.71
25.86
20.16
24.15
23.68
17.26
8.54
14.86
12.59
13.03
13.86
Working Capital
24,861
29,361
34,500
48,516
59,718
62,965
78,945
84,849
79,642
71,626
78,700
56,787
41,552
47,928
LT Debt
1,374
- -
- -
- -
- -
- -
73
352
167
1,918
1,359
759
271
549
Total Equity
44,914
56,490
65,486
75,256
86,554
94,901
107,747
118,883
127,021
124,467
134,451
143,735
165,006
176,045
Return on Invested Capital (%)
- -
- -
15.6
15.5
15.16
10.42
13.21
10.53
7.94
3.02
5.13
5.17
- -
6.6
Return on Capital (%)
- -
- -
16.35
15.95
15.78
11.03
14.4
12.69
8.03
3.99
8.24
7.38
- -
7.88
Return on Common Equity (%)
5.44
18.77
16.89
16.34
15.92
11.03
14.41
12.71
8.05
3.99
8.31
7.41
7.36
7.91

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
715
701
829
LT Borrowings
- -
- -
- -
LT Finance Leases
460
271
549
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
17
17
Market Capitalization
109,053
119,521
234,351

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
59,180
67,155
68,963
Cash, Cash Equivalents & STI
31,120
39,796
34,704
Accounts Receivable, Net
12,599
11,027
10,930
Inventories
14,135
13,511
12,807
Total Current Liabilities
23,812
25,603
21,036
Payables & Accruals
- -
- -
- -
ST Debt
715
701
829
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.8%
6.91%
14.8%
Free Cash Flow
-48.81%
-132.68%
71.17%
Net Income, GAAP
8.59%
8%
10.18%
Sales/Revenue/Turnover
8.9%
7.91%
6.42%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
18,679
20,935
19,310
22,980
81,905
2025
18,729
21,793
24,075
22,565
87,161
2026
23,192
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
157
159
100
259.21
675
2025
77
186.32
209.16
259.2
731
2026
149.52
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
99.92
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sang-Ho Shim
Full Time Employees
250
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Cheongju-si South Korea
IPO Date
Dec 3, 2010
Website
optuspharm.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
OPTUS Pharmaceutical Co., Ltd. is a South Korea-based pharmaceutical company primarily engaged in the research, development, manufacture, and commercialization of ophthalmic therapeutics, consumer eye care products, and contract manufacturing services. Founded in 2002 and headquartered in Cheongju-si, South Korea, the company operates as a key consolidated subsidiary of Samchundang Pharm Co., Ltd. OPTUS Pharmaceutical specializes in preservative-free, single-dose (unit-dose) and multi-dose ophthalmic solutions across prescription (ETC) and over-the-counter (OTC) segments. Its core pharmaceutical portfolio encompasses dry eye syndrome therapies such as Tearin F (sodium hyaluronate), Dry Free (cyclosporine), and Diqua Free (diquafosol tetrasodium); anti-infective and antibacterial solutions such as Ophthaloxin (moxifloxacin); anti-allergic and anti-inflammatory eye drops; treatments for glaucoma, steroids, and retinal disorders; and artificial tear formulations such as Dr.Fresh F (carboxymethylcellulose). Under its consumer total eye care umbrella brand OUE& (Open Ur Eyes), the company distributes OTC ophthalmic drops via its OUESOO brand, including Piaren; vision-focused functional dietary supplements via its OUEFIT brand; and ocular-area cosmeceuticals and blue-light protection skincare via its OUELAB brand. In addition, OPTUS Pharmaceutical provides contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO) services to domestic and international pharmaceutical partners, utilizing advanced aseptic blow-fill-seal (BFS) production technology. In recent operational developments, the company rebranded from DHP Korea Co., Ltd. to OPTUS Pharmaceutical Co., Ltd. to support its global expansion strategy. To scale its manufacturing footprint to cGMP standards, the company executed an investment of approximately KRW 86 billion to construct its advanced Osong Plant 2 facility, integrating automated quality and electronic management systems. Furthermore, OPTUS Pharmaceutical expanded its therapeutic pipeline by securing exclusive South Korean licensing and distribution rights from US-based Orasis Pharmaceuticals for QLOSI (pilocarpine hydrochloride ophthalmic solution 0.4%), a novel preservative-free eye drop for the treatment of presbyopia.